Press Release

Aegon Appoints Will Fuller as President and CEO of Transamerica

Issued by Aegon

Mar. 22, 2021

Aegon announced today that Will Fuller (50, American), formerly Executive Vice President of Lincoln Group, will succeed Mark Mullin as President and CEO of Transamerica, and as a member of the Management Board of Aegon N.V., effective March 31, 2021. Mark Mullin, who served as President and CEO for 11 years, will become the new Chairman of the Transamerica Corporation Board of Directors, succeeding Don Shepard, who has retired. 

Lard Friese, CEO of Aegon Group, said: “I am excited to welcome Will to our company. He is a proven financial services leader with a distinguished track record. His deep understanding of our industry and personal drive make him the right person to lead our US business into the next stage of our transformation”.

Will Fuller has worked for nearly 30 years in insurance, annuities, retirement plans and wealth management, leading Lincoln’s strategic shifts on product and the growth and diversification of distribution sources. Will also served as cochair of Lincoln’s Diversity & Inclusion Committee, and he will bring this commitment to a diverse and inclusive workplace to his new role at Transamerica.

“I am grateful for Mark’s many contributions to the company. During his eleven-year tenure as CEO, he has overseen a wide array of new and creative solutions for customers, significant restructuring, system modernization, and a refresh of the strong Transamerica brand. I am very pleased that Mark will assist with the transition to Will and that we will continue to benefit from his experience and knowledge as Chairman of the Transamerica Corporation Board of Directors”, said Lard Friese.

Mark Mullin worked for Aegon/Transamerica for 33 years, holding several leadership positions related to investments and the pension business, culminating in his appointment as President and CEO in 2009.

Editor's note: This press release has been issued by the company named above, not BenefitsLink. Reliance on information in this press release might be prudent only after an independent review of its accuracy, completeness, efficacy, and timeliness. Reference to any specific commercial product, process, or service by trade name, trademark, service mark, manufacturer, or otherwise does not constitute or imply endorsement, recommendation, or favoring by BenefitsLink.